In healthy elderly volunteers, 65 years +, vardenafil’s half-life did not suffer a notable reduction from that or younger voulunteers (45 years and younger). There is a 52% higher AUC in the average elderly male than that of a younger male, that is within a clinical trials observed variability. Placebo monitored clinical trials produced no signs of an overall safety or effectiveness difference between older and younger volunteers.
A control group of patients with an average renal function had comparable vardenafil pharmacokinetics to that of patients with severe (CLcr < 30 mL/min), moderate (CLcr 30 – 50 mL/min), or mild (CLcr 50 – 80 mL/min) renal impairment. Vardenafil plasma exposure and creatinine clearance (Cmax and AUC) depicted no apparent statistical correlation of significance. This data shows that renal function imparment is not grounds for dose adjustment.
Patients using dialysis should not use vardenafil, as the pharmacokinetics of vardenafil have yet to be observed in such a situation.
Canadian Vardenafil clearance, in patients with a mild to modest hepatic handicap (Child-Pugh A and B), was reduced in accordance.
Vardenafil Cmax and AUC were multiplied 1.2 times (Cmax by 22% and AUC by 17%) more than a healthy controlled subject after patients with a mild hepatic handicap took a 10mg dose. Adjusting dosage for mild hepatic impairments is not required. LEVITRA (vardenafil) Cmax multiplied 2.3 times (a 130% increase) and AUC multiplied 2.6 times (a 160% increase) more than a healthy controlled subject did after patients with a moderate hepatic handicap took a 10mg dose. Based on this a 5mg starting dose, which might eventually be upped to 10 or 20 mg, depending largely on efficacy and tolerability, should be utilized in patients with a moderate hepatic handicap. Individuals with a serious hepatic impairment (Child-Pugh C) should refrain from using vardenafil, as the pharmacokinetics of such a situation has yet to be researched.
In a few patients, a 20 mg dose of vardenafil produced an erection firm enough for sexual penetration (=60% rigidity) in only fifteen minutes during a placebo controlled Rigiscan study. 25 minutes after taking generic vardenafil, the statistical significance compared to placebo of the patients overall response became evident.
In every major efficacy trial, generic Vardenafil produced clinically substantial as well as statistically important improvement to erectile function compared to placebo, even including special population.
Vardenafil pills was issued to more than 3750 men battling with erectile dysfuction (ED) over the course of all trials. The men were aged between 18 and 89 years and a good number of them possessed multiple other medical conditions. More than 1630 patients took cheap vardenafil for at least 6 months.
The International Index of Erectile Function (IIEF) erectile function domain score captured that vardenafil 10 mg and 20 mg created clinically substantial as well as statistically important improvements compared to placebo in every major efficacy trial; this includes patients battling diabetes and post-prostatectomy patients. The percentage has improved with both patients rating their erections and the amount of patients who gain and maintain erections. (Tables 1 and 2).